Pfizer Reports Top-Line Results of Study of Lyrica's Effect on Male Reproduction Conducted as a Post-Approval Commitment Required by the U.S. Food and Drug Administration
Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica® (pregabalin) capsules CV Study A0081104 – Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers – demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo.1 The study was conducted as a post-approval commitment required by the US Food and Drug Administration (FDA).1 Pfizer will continue to further analyze the study results.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.